Issues pertaining to drug pricing and reimbursement, transparency and patient access. S 652 / HR 2620 "Safe Step Act," all provisions. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act," all provisions relating to prescription drug pricing and taxes. HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 830 "HELP Ensure Copays Act," all provisions.
Duration: November 17, 2015
to
October 5, 2023
General Issues: Health Issues , Taxation/Internal Revenue Code , Government Issues , Small Business , Copyright/Patent/Trademark , Budget/Appropriations , Medical/Disease Research/Clinical Labs , Medicare/Medicaid
Spending: about $36,730,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Treasury - Dept of, Veterans Affairs - Dept of (VA), Office of Policy Development
Related Foreign Entities:
Horizon Pharma plc (Dublin 4, D04 C5Y6, IRL); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) in-house lobbying effort was terminated on Jan. 19
Original Filing: 301531178.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. S 652 / HR 2620 "Safe Step Act," all provisions. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act," all provisions relating to prescription drug pricing and taxes. HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 830 "HELP Ensure Copays Act," all provisions.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301512379.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. S 652 / HR 2620 "Safe Step Act," all provisions. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act," all provisions relating to prescription drug pricing and taxes. HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 830 "HELP Ensure Copays Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301489877.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. S 652 / HR 2620 "Safe Step Act," all provisions. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act," all provisions relating to prescription drug pricing and taxes. HR 19 "Lower Costs, More Cures Act of 2021," all provisions. Issues pertaining to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 830 "HELP Ensure Copays Act," all provisions. HR 6963 "Accelerated Approval Integrity Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301462692.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. S 652 "Safe Step Act," all provisions. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act," all provisions relating to prescription drug pricing and taxes. HR 19 "Lower Costs, More Cures Act of 2021," all provisions. Issues pertaining to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 830 "HELP Ensure Copays Act," all provisions. HR 6963 "Accelerated Approval Integrity Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301435983.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. HR 2163 /S 464 "Safe Step Act," all provisions. Issues pertaining to the Healthy Futures Task Force, Request for Information. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act of 2022," all provisions relating to drug pricing and taxes. HR 5260 "Reduced Costs and Continued Cures Act," all provisions. Issues relating to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 6963 "Accelerated Approval Integrity Act," all provisions. Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301416886.xml
Lobbying Issues
Issues pertaining to the Healthy Futures Task Force. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act of 2022," all provisions relating to drug pricing and taxes. HR 5260 "Reduced Costs and Continued Cures Act," all provisions. Issues relating to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 6963 "Accelerated Approval Integrity Act," all provisions. Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) amended a lobbying report for in-house lobbying in Q22022 on Sept. 16, 2022
Original Filing: 301400265.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. HR 2163/S 464 "Safe Step Act, all provisions. Issues pertaining to the Healthy Futures Task Force, Request for Information. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. S 909 "Prescription Drug Price Relief Act," all provisions. HR 5376 "To Provide for Reconciliation Pursuant to Title II of S. Con. Res. 14," all provisions relating to drug pricing and tax. HR 5260 "Reduced Costs and Continued Cures Act," all provisions. HR 19 Lower Costs, More Cures Act of 2021, all provisions. Issues relating to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 6963 "Accelerated Approval Integrity Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301392243.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. HR 2163/S 464 "Safe Step Act, all provisions. Issues pertaining to the Healthy Futures Task Force, Request for Information. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. S 909 "Prescription Drug Price Relief Act," all provisions. HR 5376 "To Provide for Reconciliation Pursuant to Title II of S. Con. Res. 14," all provisions relating to drug pricing and tax. HR 5260 "Reduced Costs and Continued Cures Act," all provisions. HR 19 Lower Costs, More Cures Act of 2021, all provisions. Issues relating to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 6963 "Accelerated Approval Integrity Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301366742.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. HR 2163/S. 464 "Safe Step Act, all provisions. Issues pertaining to the Healthy Futures Task Force, Request for Information. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. S 909 "Prescription Drug Price Relief Act," all provisions. HR 5376 "To Provide for Reconciliation Pursuant to Title II of S. Con. Res. 14," all provisions relating to drug pricing and tax. HR 5260 "Reduced Costs and Continued Cures Act," all provisions. HR 19 Lower Costs, More Cures Act of 2021, all provisions. Issues relating to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III) and the Medical Device User Fee Amendments (MDUFA V). HR 6963 "Accelerated Approval Integrity Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Jan. 19, 2022.
Original Filing: 301328522.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. HR 2163/S 464 "Safe Step Act," all provisions. Issues pertaining to CMS Rule CMS-1751-P, all provisions relating to telehealth flexibilities and social determinants of health. Issues pertaining to Social Determinants of Health (SDOH), including SDOH Caucus Request for Information. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Food and Drug Administration Proposed Rule, Docket No. FDA-2019-N-5711, Importation of Prescription Drugs, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues pertaining to CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. Issues pertaining to CMS-55238-IFC relating to Medicare Program "Most Favored Nations Model," all provisions. HR 1425 Patient Protection and Affordable Care Enhancement Act, Title III, Lowering Prices through Fair Drug Price Negotiations, all provisions. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Proposed Rule "Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Part Liability (TPL) Requirements [Docket No. CMS 2020-0072], all provisions. S909 "Prescription Drug Price Relief Act," all provisions. HR 3684 "Infrastructure Investment and Jobs Act," all provisions. HR 5376 "To Provide for Reconciliation Pursuant to Title II of S. Con. Res. 14," all provisions relating to drug pricing and tax provisions. HR 5260 "Reduced Costs and Continued Cures Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Oct. 18, 2021.
Original Filing: 301302652.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. HR 2163/S 464 "Safe Step Act," all provisions. Issues pertaining to CMS Rule CMS-1751-P, all provisions relating to telehealth flexibilities and social determinants of health. Issues pertaining to Social Determinants of Health (SDOH), including SDOH Caucus Request for Information. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Food and Drug Administration Proposed Rule, Docket No. FDA-2019-N-5711, Importation of Prescription Drugs, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues pertaining to CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. Issues pertaining to CMS-55238-IFC relating to Medicare Program "Most Favored Nations Model," all provisions. HR 1425 Patient Protection and Affordable Care Enhancement Act, Title III, Lowering Prices through Fair Drug Price Negotiations, all provisions. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Proposed Rule "Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Part Liability (TPL) Requirements [Docket No. CMS 2020-0072], all provisions. S909 "Prescription Drug Price Relief Act," all provisions. HR 3684 "Infrastructure Investment and Jobs Act," all provisions. HR 5376 "To Provide for Reconciliation Pursuant to Title II of S. Con. Res. 14," all provisions relating to drug pricing and tax issues. HR 5260 "Reduced Costs and Continued Cures Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301288572.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Food and Drug Administration Proposed Rule, Docket No. FDA-2019-N-5711, Importation of Prescription Drugs, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues pertaining to CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. Issues pertaining to CMS-55238-IFC relating to Medicare Program "Most Favored Nations Model," all provisions. HR 1425 Patient Protection and Affordable Care Enhancement Act, Title III, Lowering Prices through Fair Drug Price Negotiations, all provisions. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Interim Final Rule Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (CMS-1744-IFC), all provisions relating to infusion at-home. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Interim Final Rule Medicare and Medicaid Programs, Basic Health Program, and Exchanges; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency and Delay of Certain Reporting Requirements for the Skilled Nursing Facility Quality Reporting Program (CMS-5531 IFC), all provisions relating to telemedicine. HR 1319 American Rescue Plan Act of 2021, all provisions relating to removal of Medicaid rebate cap provision. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Proposed Rule Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Part Liability (TPL) Requirements [Docket No. CMS 2020-0072], all provisions. S 909 "Prescription Drug Price Relief Act," all provisions. Issues pertaining to the Defense Production Act and the manufacturing of pharmaceutical products.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on April 19, 2021.
Original Filing: 301256001.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Food and Drug Administration Proposed Rule, Docket No. FDA-2019-N-5711, Importation of Prescription Drugs, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues pertaining to CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. Issues pertaining to CMS-55238-IFC relating to Medicare Program "Most Favored Nations Model," all provisions. HR 1425 Patient Protection and Affordable Care Enhancement Act, Title III, Lowering Prices through Fair Drug Price Negotiations, all provisions. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Interim Final Rule Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (CMS-1744-IFC), all provisions relating to infusion at-home. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Interim Final Rule Medicare and Medicaid Programs, Basic Health Program, and Exchanges; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency and Delay of Certain Reporting Requirements for the Skilled Nursing Facility Quality Reporting Program (CMS-5531 IFC), all provisions relating to telemedicine. HR 1319 American Rescue Plan Act of 2021, all provisions relating to removal of Medicaid rebate cap provision. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Proposed Rule Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Part Liability (TPL) Requirements [Docket No. CMS 2020-0072], all provisions. S 909 "Prescription Drug Price Relief Act," all provisions. Issues pertaining to the Defense Production Act and the manufacturing of pharmaceutical products.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Jan. 20, 2021.
Original Filing: 301238734.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Food and Drug Administration Proposed Rule, Docket No. FDA-2019-N-5711, Importation of Prescription Drugs, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues pertaining to CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. Issues pertaining to CMS-55238-IFC relating to Medicare Program "Most Favored Nations Model," all provisions. HR 1425 Patient Protection and Affordable Care Enhancement Act, Title III, Lowering Prices through Fair Drug Price Negotiations, all provisions. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Interim Final Rule Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (CMS-1744-IFC), all provisions relating to infusion at-home. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Interim Final Rule Medicare and Medicaid Programs, Basic Health Program, and Exchanges; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency and Delay of Certain Reporting Requirements for the Skilled Nursing Facility Quality Reporting Program (CMS-5531 IFC), all provisions relating to telemedicine. HR 4996 Helping MOMS Act of 2020, all provisions relating to Medicaid reforms. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Proposed Rule Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements [Docket No. CMS 2020-0072], all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Oct. 19, 2020.
Original Filing: 301215836.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Food and Drug Administration Proposed Rule, Docket No. FDA-2019-N-5711, Importation of Prescription Drugs, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues pertaining to CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. HR 1425 Patient Protection and Affordable Care Enhancement Act, Title III, Lowering Prices through Fair Drug Price Negotiations, all provisions. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Interim Final Rule Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (CMS-1744-IFC), all provisions relating to infusion at-home. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Interim Final Rule Medicare and Medicaid Programs, Basic Health Program, and Exchanges; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency and Delay of Certain Reporting Requirements for the Skilled Nursing Facility Quality Reporting Program (CMS-5531 IFC), all provisions relating to telemedicine. HR 4996 Helping MOMS Act of 2020, all provisions relating to Medicaid reforms. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Proposed Rule Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Part Liability (TPL) Requirements [Docket No. CMS 2020-0072], all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2020
In Q2, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on July 17, 2020.
Original Filing: 301192587.xml
Lobbying Issues
Issues pertaining to drug pricing and reimbursement, transparency and patient access. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Food and Drug Administration Proposed Rule, Docket No. FDA-2019-N-5711, Importation of Prescription Drugs, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues pertaining to CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. HR 1425 Patient Protection and Affordable Care Enhancement Act, Title III, Lowering Prices through Fair Drug Price Negotiations, all provisions. Issues pertaining to Medicare Interim Final Rule Revisions in Response to the COVID-19 Public Health Emergency (CMS-1744-IFC), all provisions relating to infusion at-home. Issues pertaining toMedicare and Medicaid Interim Final Rule Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (CMS-5531 IFC), all provisions relating to telemedicine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301177097.xml
Lobbying Issues
CMS Rule CMS-1711-P relating to Medicare and Medicaid Programs, "CY 2020 Home Health Prospective Payment System Rate Update, Home Health Value-Based Purchasing Model, Home Health Quality Reporting Requirements, and Home Infusion Therapy Requirements," all provisions. H Res 242 "Affirming the importance of the Orphan Drug Act," all provisions. HR 748 / S 3548 "CARES Act," all provisions pertaining to corporate tax, and CMS home infusion benefits. HR 19 "Lower Costs, More Cures Act of 2019," all provisions. HR 2113 Prescription Drug STAR Act, all provisions. HR 2296 More Efficient Tools to Realize Information for Consumers Act, all provisions. HR 3 "Elijah E. Cummings Lower Drug Costs Now Act," all provisions. Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Importation of Prescription Drugs Proposed Rule, Food and Drug Administration (FDA), [Docket No. FDA-2019-N-5711]. Issues relating to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. S 1391 "Fair Accountability and Innovative Research Drug Pricing Act of 2019, all provisions. S 474 Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019, all provisions. Issues relating to creating a cystinosis disease awareness day on May 7th. S 2543 Prescription Drug Pricing Reduction Act of 2019, all provisions in Amendment #4 Improving Metrics for Price Reporting for Orphan Drugs Act. CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. S 1895 Lower Health Care Costs Act, all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2019
In Q4, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Jan. 19, 2020.
Original Filing: 301121847.xml
Lobbying Issues
Regulation CMS-1711-P "CY 2020 Home Health Prospective Payment System Rate Update, Home Health Value-Based Purchasing Model, Home Health Quality Reporting Requirements, and Home Infusion Therapy Requirements," all provisions. Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to drug pricing transparency. HR 2296 FAIR Drug Pricing Act of 2019, all provisions. S 4743 Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019, all provisions. HR 2113 Prescription Drug STAR Act, all provisions. HR 2296 More Efficient Tools to Realize Information for Consumers (METRIC) Act, all provisions. Issues related to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. H Res 242 Orphan Drug Act, all provisions. HR 1503 "Orange Book Transparency Act of 2019," provisions in Section 2 relating to the Orange Book. HR 107 To amend title XIX of Social Security Act, all provisions. Issues related to creating a cystinosis disease awareness day on May 7th. Office of the Inspector General (HHS) Rule OIG-0936-P relating to Fraud and Abuse, Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, all provisions. CMS Rule CMS-5528-ANPRM relating to Medicare Program, International Pricing Index Model for Medicare Part B Drugs, all provisions. Issues related to importation of pharmaceuticals. S 2543 Prescription Drug Pricing Reduction Act of 2019, all provisions in Amendment #4 Improving Metrics for Price Reporting for Orphan Drugs Act. HR 3 "Lower Drug Costs Now Act of 2019," all provisions. Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions. S 1895 Lower Health Care Costs Act, all provisions. HR 259 Medicaid Extenders Act of 2019, all provisions. HR 19 Lower Costs, More Cures Act of 2019, all provisions.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301075920.xml
Lobbying Issues
Regulation CMS-1711-P "CY 2020 Home Health Prospective Payment System Rate Update; Home Health Value-Based Purchasing Model; Home Health Quality Reporting Requirements; and Home Infusion Therapy Requirements," all provisions. Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to drug pricing transparency. HR 2296 FAIR Drug Pricing Act of 2019, all provisions. S 4743 Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019, all provisions. HR 2113 Prescription Drug STAR Act, all provisions. HR 2296 More Efficient Tools to Realize Information for Consumers (METRIC) Act, all provisions. Issues related to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. H Res 242 Orphan Drug Act, all provisions. HR 1503 "Orange Book Transparency Act of 2019," provisions in Section 2 relating to the Orange Book. HR 107 To amend title XIX of Social Security Act, all provisions. Issues related to creating a cystinosis disease awareness day on May 7th. Office of the Inspector General (HHS) Rule OIG-0936-P, all provisions pertaining to Fraud and Abuse; Issues related to the removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. CMS Rule CMS-5528-ANPRM relating to Medicare Program, all provisions. Issues related to an International Pricing Index Model for Medicare Part B Drugs. Issues related to importation of pharmaceuticals. S 102 " Prescription Drug Price Relief Act of 2019," all provisions. HR 3 " Lower Drug Costs Now Act of 2019," all provisions.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301057851.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to drug pricing transparency. HR 2296 FAIR Drug Pricing Act of 2019, all provisions. S 4743 Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019, all provisions. HR 2113 Prescription Drug STAR Act, all provisions. HR 2296 More Efficient Tools to Realize Information for Consumers (METRIC) Act, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. H Res 242 Orphan Drug Act, all provisions. HR 1503 "Orange Book Transparency Act of 2019," provisions in Section 2 relating to the Orange Book. HR 107 To amend title XIX of Social Security Act, all provisions. Issues pertaining to creating a cystinosis disease awareness day on May 7th. Office of the Inspector General (HHS) Rule OIG-0936-P relating to Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. CMS Rule CMS-5528-ANPRM relating to Medicare Program; International Pricing Index Model for Medicare Part B Drugs. Issues pertaining to importation of pharmaceuticals.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301037410.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 1503 "Orange Book Transparency Act of 2019," all provisions. H Res 242 "Affirming the importance of the Orphan Drug Act, celebrating the over 750 new orphan therapies approved since its creation, and recognizing the need to continue supporting research and development for rare diseases," all provisions.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2019.
Original Filing: 301014531.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 4710 "340B Protecting Access for the Underserved and Safety-net Entities Act," all provisions. S 2312 "Helping Ensure Low-income Patients have Access to Care and Treatment" (HELP Act), all provisions. S 2453 "Ensuring the Value of the 340B Program Act of 2018," all provisions. HR 5598 "340B Optimization Act," all provisions. HR 6071 "SERV Communities Act," all provisions. HR 6240 "Drug Discount Accountability Act," all provisions.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on Oct. 22, 2018.
Original Filing: 300995086.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 4710 "340B Protecting Access for the Underserved and Safety-net Entities Act," all provisions. S 2312 "Helping Ensure Low-income Patients have Access to Care and Treatment" (HELP Act), all provisions. S 2453 "Ensuring the Value of the 340B Program Act of 2018," all provisions. HR 5598 "340B Optimization Act," all provisions. HR 6071 "SERV Communities Act," all provisions. HR 6240 "Drug Discount Accountability Act," all provisions.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on July 19, 2018.
Original Filing: 300972000.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 4710 "340B Protecting Access for the Underserved and Safety-net Entities Act," all provisions. S 2312 "Helping Ensure Low-income Patients have Access to Care and Treatment" (HELP Act), all provisions. S 2453 "Ensuring the Value of the 340B Program Act of 2018," all provisions. HR 5598 "340B Optimization Act," all provisions. HR 6071 "SERV Communities Act," all provisions. HR 6240 "Drug Discount Accountability Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1 "Tax Cuts and Jobs Act," all provisions pertaining to business tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on April 19, 2018.
Original Filing: 300951894.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and federal programs. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 4710 "340B Protecting Access for the Underserved and Safety-net Entities Act," all provisions. S 2312 "Helping Ensure Low-income Patients have Access to Care and Treatment" (HELP Act), all provisions. S 2453 "Ensuring the Value of the 340B Program Act of 2018," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1 "Tax Cuts and Jobs Act," all provisions pertaining to business tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S 2039 "Disclosing Foreign Influence Act," all provisions pertaining to the LDA filing exemption.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on Jan. 19, 2018.
Original Filing: 300930880.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and to Section 340B. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 4710 "340B Protecting Access for the Underserved and Safety-net Entities Act," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to discussion draft of "Better Way for Tax Reform," all provisions pertaining to business tax reform. Issues relating to discussion draft of "Unified Framework for Fixing our Broken Tax Code," all provisions pertaining to business tax reform. H.R. 1 "Tax Cuts and Jobs Act," all provisions pertaining to business tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300913070.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and to Sections 7101 and 7102. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to discussion draft of pending "Better Way for Tax Reform," all provisions pertaining to business tax reform. Issues relating to discussion draft of pending "Unified Framework for Fixing our Broken Tax Code," all provisions pertaining to business tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300897070.xml
Lobbying Issues
HR 1628 "American Health Care Act of 2017," provisions pertaining to Subsection 2203(a)(4). HR 1245/S 469 "Affordable and Safe Prescription Drug Importation Act," all provisions. S 92 "Safe and Affordable Drugs from Canada Act of 2017," all provisions. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and to Section 7102. Issues pertaining to Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to discussion draft of pending "Better Way for Tax Reform," all provisions pertaining to business tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on April 19, 2017.
Original Filing: 300871571.xml
Lobbying Issues
HR 1628 "American Health Care Act of 2017," provisions pertaining to Subsection 2203(a)(4). HR 1245/S 469 "Affordable and Safe Prescription Drug Importation Act," all provisions. S 92 "Safe and Affordable Drugs from Canada Act of 2017," all provisions. Issues related to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI) and to Section 7102.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to discussion draft of pending "Better Way for Tax Reform," all provisions.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on Jan. 19, 2017.
Original Filing: 300851999.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI). S 1878 "Advancing Hope Act of 2016," all provisions pertaining to extension of pediatric rare diseases priority review voucher program (PRV). HR 6 "21st Century Cures Act," all provisions relating to drug development and patient access. HR 5122 "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models," all provisions.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300836460.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI). S 1878 "Advancing Hope Act of 2016," all provisions pertaining to extension of pediatric rare diseases priority review voucher program (PRV). HR 6 "21st Century Cures Act," all provisions relating to drug development and patient access. HR 5122 "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models," all provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to Treasury and IRS proposed regulations under Section 385, all provisions.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on July 20, 2016.
Original Filing: 300818476.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI). S 1878 "Advancing Hope Act of 2016," all provisions pertaining to extension of pediatric rare diseases priority review voucher program (PRV). HR 6 "21st Century Cures Act," all provisions relating to drug development and patient access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to Treasury and IRS proposed regulations under Section 385, all provisions.
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
In Q1, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300803611.xml
Lobbying Issues
Issues related to the implementation of PL 111-148 "Patient Protection and Affordable Care Act," all provisions pertaining to the Center for Medicare and Medicaid Innovation (CMMI). S 1878 "Advancing Hope Act of 2016," all provisions pertaining to extension of pediatric rare diseases priority review voucher program (PRV). HR 6 "21st Century Cures Act," all provisions relating to drug development and patient access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 4139 "Fostering Innovation Act of 2015," all provisions.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2015
In Q4, Horizon Pharma USA, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300784264.xml
Lobbying Issues
HR 9 "Innovation Act," all provisions related to post-grant review reform. S 1137 "PATENT Act," all provisions related to post-grant review reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues pertaining to draft legislation called "Innovations for Healthier Americans," all provisions related to drug development & patient access. HR 6 "21st Century Cures Act," all provisions related to drug development & patient access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 2029 "Consolidated Appropriations Act 2016," all provisions related to corporate tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
Horizon Pharma USA, Inc. filed a lobbying registration on Jan. 4, 2016 for in-house lobbying efforts, effective Nov. 17, 2015.
Original Filing: 300769009.xml
Issue(s) they said they’d lobby about: Legislative and regulatory issues related to biotechnology pharmaceuticals. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...